Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US

Novartis will be the first pharmaceutical company to bring a CAR-T cancer therapy to market in the U.K., as the country's National Health Service announced Wednesday it had reached a funding deal for the Swiss drugmaker's Kymriah.